

18 May 2021

## June 2021 Pharmaceutical Schedule Dispatch

Kia ora

This is an early notification of the changes to be announced in the **June 2021** Update to the Pharmaceutical Schedule.

The full Update will be available as a [PDF on our website](#). The changes will be published in the online Schedule around the 23<sup>rd</sup> of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz).

### New listings

- Calcium folinate (Calcium Folate Sandoz S29) inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist, S29 and wastage claimable (p'code 2611368)
- Calcium folinate (Calcium Folate Sandoz S29) inj 10 mg per ml, 35 ml vial – PCT only – Specialist, S29 (p'code 2611341)
- Digoxin (Lanoxin Paediatric Elixir) oral liq 50 mcg per ml, 60 ml – (p'code 2611562)
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 U – Xpharm, for patients with haemophilia, new Pharmacode listing (p'code 2583992)
- Hydrocortisone acetate (Cortifoam) rectal foam 10%, CFC-free (14 applications), 15 g OP– S29 (p'code 2608707)
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Baxter) inj 1%, 5 ml ampoule – up to 25 inj available on a PSO (p'code 2599872)
- Paracetamol (Noumed Paracetamol) tab 500 mg – bottle pack – Maximum of 300 tab per prescription can be waived by endorsement (p'code 2611430)

### Changes to restrictions, chemical names and presentations

- Ambrisentan (Ambrisentan Mylan) tab 5 mg and 10 mg – brand switch fee removed
- Clarithromycin tab 250 mg (Apo-Clarithromycin) and grans for oral liq 250 mg per 5 ml (Klacid) – amended restriction criteria
- Oxybutynin (Apo-Oxybutynin) tab 5 mg and oral liq 5 mg per 5 ml - addition of subsidy by endorsement
- Multiple sclerosis treatments – amended Special Authority criteria
- Standard Formulae – Magnesium hydroxide 8% mixture – standard formulae removed
- Temozolomide (Temaccord, Apo-Temozolomide, Accord) cap 20 mg – removal of no co-payment payable

## Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Ciprofloxacin	Eye drops 0.3%, 5 ml OP	Ciprofloxacin Teva	
Diclofenac sodium	Eye drops 0.1%, 5 ml OP	Voltaren Ophtha	
Disulfiram	Tab 200 mg	Antabuse	
Hydrocortisone	Inj 100 mg vial	Solu-Cortef	